ALK(SZ:002940) Hua Yuan Zheng Quan·2025-10-20 07:49Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company's partner, Affinivax, has had its first innovative drug, Legobix, selected for ESMO 2025 LBA reporting, demonstrating excellent efficacy and safety, which continues to validate the platform's value. The company has introduced its first innovative drug, ALK-N001, based on the same platform design, which is worth close attention [5][7] - The clinical trial data for Legobix shows significant improvements over existing chemotherapy options, with a marked reduction in toxicity, particularly in cardiac and hematological side effects [9] Financial Summary - The company is expected to achieve net profits of 120 million, 150 million, and 190 million yuan for 2025-2027, with year-on-year growth rates of 44%, 29%, and 27% respectively. The current stock price corresponds to P/E ratios of 78, 60, and 48 times for the same years [5][8] - Revenue projections for 2025 are estimated at 1.598 billion yuan, with a year-on-year growth rate of 3.90% [8] - The company's gross margin is projected to improve from 40.13% in 2024 to 42.92% in 2027, indicating a positive trend in profitability [10]